Tengion (TNGN) 0.1475 $TNGN
Tengion Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Mar 26, 3:05PM CDT
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2013 and provided a business update.
Tallwave Expands High Tide Lean Business Competition to Include Ed Tech and Healthcare IT From Across the Country and Adds Industry Agnostic "Wildcard" Slots for Arizona IT Startups
Marketwire - Thu Mar 13, 2:14PM CDT
Tallwave today announced it is opening applications in its latest High Tide(TM) competition to Healthcare IT entrepreneurs from across the country. These entrepreneurs will join peers applying for the program in the previously announced focus on innovations in Ed Tech. In addition, Tallwave has reserved four to six slots for Arizona-only IT companies regardless of the industry sector they hail from. The deadline for submission is March 31, 2014 and can be completed online at www.tallwavehightide.com.
Tengion to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 3:30PM CST
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 26th Annual ROTH Conference on Monday, March 10, 2014, at 12:30 p.m. PDT in Dana Point, CA.
Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets
Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
PR Newswire - Wed Aug 14, 3:05PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the second quarter ended June 30, 2013.
OTC Daily Alert Stock Watch - Tengion (OTCQB: TNGN)
WorldStockWire - Sat Aug 10, 7:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Tengion Announces Promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance
PR Newswire - Wed Aug 07, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance. Mr. Davis has served as Chief Financial Officer of Tengion since joining the Company in 2010 and recently helped facilitate the Company in raising $33.6M to fund research and development activities for its two lead clinical programs, the Neo-Kidney Augment(TM) and the Neo-Urinary Conduit(TM).
Market Maker Surveillance Report. OSTK, STXS, ZHNE, TNGN, GAME, HGSH, Winning Stocks With Lowest Price Friction For Thursday, July 18th 2013
M2 - Fri Jul 19, 2:05AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3821 companies with "abnormal" market making, 3241 companies with positive Friction Factors and 1918 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Overstock.com Inc (NASDAQ:OSTK), Stereotaxis Inc (NASDAQ:STXS), Zhone Technologies Inc (NASDAQ:ZHNE), Tengion Inc (OTC:TNGN), Shanda Games Ltd (NASDAQ:GAME), China Hgs Real Estate Inc (NASDAQ:HGSH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Tengion Announces Transactions Totaling $33.6 Million to Advance its Organ Regeneration Platform(TM)
PR Newswire - Mon Jul 01, 1:41PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the closing of transactions totaling $33.6 million to fund its two lead clinical programs, the Neo-Kidney Augment(TM) and the Neo-Urinary Conduit(TM).
Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
PR Newswire - Wed Jun 12, 3:30PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting being held June 12th-15th, 2013 in Boston, Massachusetts.
Tengion Provides Business Update and Reports First Quarter 2013 Financial Results
PR Newswire - Wed May 15, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013.
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
PR Newswire - Mon Apr 01, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the acceptance of the Company's Clinical Trial Application (CTA) filed with the Medical Products Agency (MPA) in Sweden to initiate a Phase 1 clinical trial to evaluate the safety and delivery of its Neo-Kidney Augment(TM) product in up to five patients with advanced chronic kidney disease (CKD).
Tengion Provides Business Update and Reports Fourth Quarter and Full Year 2012 Financial Results
PR Newswire - Mon Mar 18, 6:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2012 and provided a business update.
Tengion to Present at 25th Annual ROTH Conference
PR Newswire - Tue Mar 12, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 25th Annual ROTH Conference on Tuesday, March 19, 2013, at 2:00 p.m. PDT in Laguna Niguel, CA.
Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013
PR Newswire - Mon Mar 11, 3:00PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m. EDT to provide a business update and discuss its fourth quarter and full year 2012 financial results.
Tengion to Present at the BIO CEO & Investor Conference
PR Newswire - Tue Feb 05, 7:00AM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that A. Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:30 a.m. EST in New York City.
Tengion Announces Clinical Progress for Neo-Urinary Conduit(TM) Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment(TM)
PR Newswire - Wed Jan 30, 3:30PM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced advances for its two lead programs, the Neo-Urinary Conduit(TM) and Neo-Kidney Augment(TM).
Tengion Announces Change to Board of Directors
PR Newswire - Fri Dec 21, 7:15AM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Scott D. Flora, President & Chief Executive Officer at OmniGuide, has resigned from Tengion's Board of Directors, effective December 19, 2012.
Regenerative Medicine - Global Strategic Business Report
M2 - Mon Dec 17, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/qhqtfr/regenerative) has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Regenerative Medicine in US$ million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 93 companies including many key and niche players such as: - BioVest International Inc. - Curis Inc. - Cytori Therapeutics Inc. - Evotec AG - Forticell Bioscience Inc. - Geron Corporation - Integra LifeSciences Corporation - LifeCell Corporation - Osiris Therapeutics Inc. - Tengion Inc. - Tepha Inc. - TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public doma
Tengion Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Mar 26, 3:05PM CDT
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2013 and provided a business update.
Tallwave Expands High Tide Lean Business Competition to Include Ed Tech and Healthcare IT From Across the Country and Adds Industry Agnostic "Wildcard" Slots for Arizona IT Startups
Marketwire - Thu Mar 13, 2:14PM CDT
Tallwave today announced it is opening applications in its latest High Tide(TM) competition to Healthcare IT entrepreneurs from across the country. These entrepreneurs will join peers applying for the program in the previously announced focus on innovations in Ed Tech. In addition, Tallwave has reserved four to six slots for Arizona-only IT companies regardless of the industry sector they hail from. The deadline for submission is March 31, 2014 and can be completed online at www.tallwavehightide.com.
Tengion to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 3:30PM CST
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 26th Annual ROTH Conference on Monday, March 10, 2014, at 12:30 p.m. PDT in Dana Point, CA.
Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets
Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
PR Newswire - Wed Aug 14, 3:05PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the second quarter ended June 30, 2013.
OTC Daily Alert Stock Watch - Tengion (OTCQB: TNGN)
WorldStockWire - Sat Aug 10, 7:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Tengion Announces Promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance
PR Newswire - Wed Aug 07, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance. Mr. Davis has served as Chief Financial Officer of Tengion since joining the Company in 2010 and recently helped facilitate the Company in raising $33.6M to fund research and development activities for its two lead clinical programs, the Neo-Kidney Augment(TM) and the Neo-Urinary Conduit(TM).
Market Maker Surveillance Report. OSTK, STXS, ZHNE, TNGN, GAME, HGSH, Winning Stocks With Lowest Price Friction For Thursday, July 18th 2013
M2 - Fri Jul 19, 2:05AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3821 companies with "abnormal" market making, 3241 companies with positive Friction Factors and 1918 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Overstock.com Inc (NASDAQ:OSTK), Stereotaxis Inc (NASDAQ:STXS), Zhone Technologies Inc (NASDAQ:ZHNE), Tengion Inc (OTC:TNGN), Shanda Games Ltd (NASDAQ:GAME), China Hgs Real Estate Inc (NASDAQ:HGSH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Tengion Announces Transactions Totaling $33.6 Million to Advance its Organ Regeneration Platform(TM)
PR Newswire - Mon Jul 01, 1:41PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the closing of transactions totaling $33.6 million to fund its two lead clinical programs, the Neo-Kidney Augment(TM) and the Neo-Urinary Conduit(TM).
Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
PR Newswire - Wed Jun 12, 3:30PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting being held June 12th-15th, 2013 in Boston, Massachusetts.
Tengion Provides Business Update and Reports First Quarter 2013 Financial Results
PR Newswire - Wed May 15, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013.
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
PR Newswire - Mon Apr 01, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the acceptance of the Company's Clinical Trial Application (CTA) filed with the Medical Products Agency (MPA) in Sweden to initiate a Phase 1 clinical trial to evaluate the safety and delivery of its Neo-Kidney Augment(TM) product in up to five patients with advanced chronic kidney disease (CKD).
Tengion Provides Business Update and Reports Fourth Quarter and Full Year 2012 Financial Results
PR Newswire - Mon Mar 18, 6:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2012 and provided a business update.
Tengion to Present at 25th Annual ROTH Conference
PR Newswire - Tue Mar 12, 7:30AM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that John L. Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming 25th Annual ROTH Conference on Tuesday, March 19, 2013, at 2:00 p.m. PDT in Laguna Niguel, CA.
Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013
PR Newswire - Mon Mar 11, 3:00PM CDT
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m. EDT to provide a business update and discuss its fourth quarter and full year 2012 financial results.
Tengion to Present at the BIO CEO & Investor Conference
PR Newswire - Tue Feb 05, 7:00AM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that A. Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:30 a.m. EST in New York City.
Tengion Announces Clinical Progress for Neo-Urinary Conduit(TM) Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment(TM)
PR Newswire - Wed Jan 30, 3:30PM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced advances for its two lead programs, the Neo-Urinary Conduit(TM) and Neo-Kidney Augment(TM).
Tengion Announces Change to Board of Directors
PR Newswire - Fri Dec 21, 7:15AM CST
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Scott D. Flora, President & Chief Executive Officer at OmniGuide, has resigned from Tengion's Board of Directors, effective December 19, 2012.
Regenerative Medicine - Global Strategic Business Report
M2 - Mon Dec 17, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/qhqtfr/regenerative) has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Regenerative Medicine in US$ million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 93 companies including many key and niche players such as: - BioVest International Inc. - Curis Inc. - Cytori Therapeutics Inc. - Evotec AG - Forticell Bioscience Inc. - Geron Corporation - Integra LifeSciences Corporation - LifeCell Corporation - Osiris Therapeutics Inc. - Tengion Inc. - Tepha Inc. - TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public doma
